• Juan Diego Alzate, Elad Mashiach, Assaf Berger, Kenneth Bernstein, Reed Mullen, Nigris VasconcellosFernando DeFDepartment of Neurological Surgery, NYU Langone Health, New York University, New York , New York , USA., Tanxia Qu, Joshua S Silverman, Bernadine R Donahue, Benjamin T Cooper, Erik P Sulman, John G Golfinos, and Douglas Kondziolka.
• Department of Neurological Surgery, NYU Langone Health, New York University, New York , New York , USA.
• Neurosurgery. 2023 Nov 1; 93 (5): 111211201112-1120.

Background And ObjectivesDose selection for brain metastases stereotactic radiosurgery (SRS) classically has been based on tumor diameter with a reduction of dose in the settings of prior brain irradiation, larger tumor volumes, and critical brain location. However, retrospective series have shown local control rates to be suboptimal with reduced doses. We hypothesized that lower doses could be effective for specific tumor biologies with concomitant systemic therapies. This study aims to report the local control (LC) and toxicity when using low-dose SRS in the era of modern systemic therapy.MethodsWe reviewed 102 patients with 688 tumors managed between 2014 and 2021 who had low-margin dose radiosurgery, defined as ≤14 Gy. Tumor control was correlated with demographic, clinical, and dosimetric data.ResultsThe main primary cancer types were lung in 48 (47.1%), breast in 31 (30.4%), melanoma in 8 (7.8%), and others in 15 patients (11.7%). The median tumor volume was 0.037cc (0.002-26.31 cm 3 ), and the median margin dose was 14 Gy (range 10-14). The local failure (LF) cumulative incidence at 1 and 2 years was 6% and 12%, respectively. On competing risk regression analysis, larger volume, melanoma histology, and margin dose were predictors of LF. The 1-year and 2-year cumulative incidence of adverse radiation effects (ARE: an adverse imaging-defined response includes increased enhancement and peritumoral edema) was 0.8% and 2%.ConclusionIt is feasible to achieve acceptable LC in BMs with low-dose SRS. Volume, melanoma histology, and margin dose seem to be predictors for LF. The value of a low-dose approach may be in the management of patients with higher numbers of small or adjacent tumors with a history of whole brain radio therapy or multiple SRS sessions and in tumors in critical locations with the aim of LC and preservation of neurological function.Copyright © Congress of Neurological Surgeons 2023. All rights reserved.

27 keywords...

hide…